The following information is furnished pursuant to both Item 2.02 and Item 7.01

On July 22, 2005, AngioDynamics, Inc. issued a press release announcing its financial results for the thirteen and fifty-two weeks ended May 28, 2005. A copy of the release is attached hereto as Exhibit 99.1 and is incorporated herein by reference in its entirety.

2

Gross profit increased 30% to $9.8 million for the fiscal 2005 fourth quarter from $7.5 million for the prior-year fourth quarter, and gross margin rose to 56.3% from 53.3%, a 300 basis point increase. This gross margin improvement is largely due to a product mix weighted more heavily toward higher margin disposable products, lower raw material costs and modest price increases implemented late in fiscal 2004 and early in fiscal 2005.

Operating profit for the 13 weeks ended May 28, 2005 increased to $2.5 million, from $1.9 million for the prior-year fourth quarter, a gain of 31%.

Net income for the fourth quarter of fiscal 2005 was $1.7 million, or $0.13 per diluted share, compared with net income of $1.5 million, or $0.15 per diluted share, for the fiscal 2004 fourth quarter. The Company’s effective income tax rate for the fiscal 2005 fourth quarter was 36%, compared with a tax rate of only 14% in the prior-year period when the Company realized a tax benefit from the utilization of capital loss carryforwards by its former parent, E-Z-EM (Nasdaq: EZEM).

Eamonn P. Hobbs, President and CEO of AngioDynamics, commented, “This quarter marked the completion of another great year at AngioDynamics and our first year as a publicly traded company. The continued sales and unit growth of the product lines on which we have particularly focused our sales support, such as the VenaCure procedure kits, and acceptance of our new products, such as the Morpheus PICC line, provide tangible evidence of our commitment to innovation and the high level of performance from our staff. Our financial performance, including gross margin improvement, is a strong testament to how well all aspects of our business are running.”

Hobbs continued, “On a more specific note about the fourth quarter, I’d like to point out that we were successful in our strategy to refocus certain sales initiatives and leverage the flexibility of our sales force. In the fiscal 2005 third quarter, we channeled resources to establish our new Morpheus CT PICC in the marketplace with great success. In the fourth quarter, we refocused our sales attention back to VenaCure. Our fourth quarter results reflect how well this approach worked as Morpheus growth remained on track while VenaCure sales increased significantly, as did its market share.”

For the 52 weeks ended May 28, 2005, net sales were $60.3 million, up 23% from net sales of $49.1 million for fiscal 2004. Gross margin for fiscal 2005 was 55.4%, representing an increase over the prior year of 280 basis points. The margin improvement is due to a product mix weighted towards higher margin disposable products, lower material costs, manufacturing efficiencies and modest price increases implemented late in fiscal 2004 and early in fiscal 2005.

Net income for fiscal 2005 increased 45% to $4.5 million, or $0.37 per diluted share, from $3.1 million, or $0.32 per diluted share, for fiscal 2004. The Company’s effective income tax rate for fiscal 2005 was 40%, compared with 28% for fiscal 2004, the increase again due to the use of capital loss carryforwards in 2004. The improvement in EPS from fiscal 2004 was partially offset by an increase in weighted average shares outstanding.